Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1)

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study will comprise of a Phase 1 dose escalation and Phase 2 evaluations of safety and efficacy. In the Phase 1 dose escalation, patients will be enrolled in sequential cohorts treated with successively higher doses of quaratusugene ozeplasmid in combination with osimertinib. When the recommended Phase 2 dose (RP2D) is determined in Phase 1, Phase 2a will be initiated and patients will be enrolled in 2 parallel, non-randomized cohorts treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.

Acclaim-1 is an open-label, multi-center, Phase 1/2 study evaluating quaratusugene ozeplasmid (Reqorsa) plus osimertinib (investigational arm) versus platinum-based chemotherapy (control arm) in patients with advanced metastatic or recurrent NSCLC. Toxicities will be assessed by the Investigator using United States National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious Adverse Events and Dose Limiting Toxicities (DLT) will be reviewed by a Safety Review Committee. Phase 1 - Dose Escalation: The RP2D of quaratusugene ozeplasmid when given in combination with osimertinib will be identified. Phase 2a: Once the RP2D of quaratusugene ozeplasmid is identified in Phase 1, 2 expansion cohorts will be enrolled to better characterize safety, tolerability, and preliminary anti-tumor activity of the combination therapy. Phase 2b: Quaratusugene ozeplasmid in combination with osimertinib will be further evaluated using the RP2D identified in Phase 1. Patients may receive local therapy, such as radiation therapy, to progressing lesions prior to enrollment. Patients will be randomized to receive either the investigational arm or the control arm in a 1 to 1 ratio and stratified based on prior local radiotherapy.

Epidermal growth factor receptor mutation (EGFR), osimertinib, Tumor suppressor gene 2 (TUSC2), Lipid nanoparticle (LNP), Gene therapy, Tagrisso, FUS1-nanoparticles, NSCLC, Reqorsa, quaratusugene ozeplasmid

Phase 1: 3+3 dose escalation to identify RP2D. Phase 2: RP2D further evaluated in Phase 2a followed by parallel randomization in a 1:1 ratio to either investigational arm or control arm.

In Phase 1, Phase 2a and the investigational arm of Phase 2b, patients will receive their assigned dose of quaratusugene ozeplasmid (intravenous administration once every 21 days) plus osimertinib (80 mg fixed dose oral tablet taken daily starting on Day 1 through Day 21 of every 21-day treatment cycle) until disease progression or unacceptable toxicity.

In the control arm of Phase 2b, patients will receive platinum-based chemotherapy until disease progression or unacceptable toxicity.

Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.

Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.

Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.

RP2D, which will be the maximum tolerated dose (MTD) or, if the MTD is not defined by the safety data, RP2D will be determined based on an integrated assessment of all available clinical safety and preliminary efficacy data.

ORR (complete response [CR]+ partial response [PR]) according to RECIST using best overall response from baseline to disease progression or death.

ORR (CR+ PR) according to RECIST using best overall response from baseline to disease progression or death.

ORR (CR+ PR) according to RECIST using best overall response from baseline to disease progression or death.

Treatment-related adverse events (AEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events.

Inclusion Criteria: Age ≥18 years. Histologically or cytologically documented NSCLC. Stage III or IV NSCLC or recurrent NSCLC that is not potentially curable by radiotherapy or surgery. EGFR mutation-positive, based on results of most recent lung cancer tissue biopsy or evaluation of circulating tumor DNA. If the most recent EGFR mutation evaluation is by circulating tumor DNA, a previous lung cancer tissue biopsy must have demonstrated NSCLC. Achieved clinical response to osimertinib for ≥4 months, which can be a response of stable disease. Must have a minimum of a 10-day osimertinib washout completed at the time of enrollment. Must have radiological progression on osimertinib treatment and can have either asymptomatic disease or symptomatic disease. In addition, the following criteria must be met based on trial phase enrollment: Phase 1 Expansion portion: Must have measurable disease per RECIST 1.1. Cohort 1 must have progression on osimertinib treatment which must be the only systemic treatment for NSCLC. Cohort 2 must either have 1) progression on osimertinib in combination with pemetrexed and a platin (carboplatin or cisplatin) administered as initial treatment for metastatic NSCLC, or 2) have progression on single agent osimertinib administered as initial treatment for metastatic NSCLC, and then progression on pemetrexed and a platin (carboplatin or cisplatin), administered with osimertinib, or pemetrexed and osimertinib. May have received prior bevacizumab in combination with the osimertinib containing regimens noted previously. No other prior systemic treatments are allowed. Phase 2: Must have measurable disease per RECIST 1.1. Must have progression on osimertinib treatment which must be the only systemic treatment for NSCLC. Eligibility for patients with symptomatic disease is restricted to those with limited metastasis (≤5 metastases). Eastern Cooperative Oncology Group performance status (ECOG PS) score from 0 to 1. Must be ≥28 days beyond major surgical procedures such as thoracotomy, laparotomy, or joint replacement, and must be ≥10 days beyond minor surgical procedures such as biopsy of subcutaneous tumors, pleuroscopy, etc., and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery per investigator assessment. Asymptomatic brain metastases must meet ALL criteria of the following: No history of seizures in the preceding 6 months. Definitive treatment must be completed ≥21 days. Must be off steroids administered because of brain metastases or related symptoms for ≥7 days. Post-treatment imaging must demonstrate stability or regression of the brain metastases. Absolute neutrophil count (ANC) >1500/mm3, platelet count >100,000/mm3 within ≤21 days. Adequate renal function documented by serum creatinine of ≤1.5 mg/dL or calculated creatinine clearance >50 ml/min within ≤21 days. Adequate hepatic function as documented by serum bilirubin <1.5 mg/dL and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X upper limit of normal (ULN) within ≤21 days. Stable cardiac condition with a left ventricular ejection fraction ≥40% within ≤21 days. If female of childbearing potential (FOCBP), must have negative serum pregnancy test (serum beta-human chorionic gonadotropin [β-hCG]) within ≤7 days. Must agree to use 2 forms of contraception including 1 highly effective and 1 effective methods (defined in Section 5.3) during the study period and for 4 months following the last dose of study treatment. If male, must agree to no sperm donation during study treatment and for an additional 4 months following the last dose of study treatment. Must have voluntarily signed an informed consent in accordance with institutional policies. Exclusion Criteria: Unable to tolerate osimertinib treatment, leading to early treatment discontinuation or prolonged/frequent dosage modifications as determined by the investigator. Received standard chemotherapy or monoclonal antibodies to treat NSCLC within ≤21 days. Received prior gene therapy. Other genetic characteristics (such as ALK, ROS, BRAF V600E mutations) which makes the patient a candidate for treatment with other approved targeted therapies. Received radiotherapy to the skull, spine, thorax, or pelvis within ≤30 days. Active systemic viral, bacterial, or fungal infection(s) requiring treatment. Serious concurrent illness or psychological, familial, sociological, geographical, or other concomitant conditions that, in the opinion of the investigator, would not permit adequate follow-up and compliance with the study protocol. History of myocardial infarction or unstable angina within ≤6 months. Known human immunodeficiency virus (HIV) infection or has active hepatitis infection. Female who is pregnant or breastfeeding.